CD33 and hematopoietic and lymphoid system neoplasm: Gemtuzumab ozogamicin (Mylotarg®) against CD33, approved for blood cancer in 2000 and 2017, was endocytosed through the endosome/lysosome pathway in CD33-expressing HL-60 cells [19].